156 related articles for article (PubMed ID: 36826137)
21. Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin.
Ueda Y; Miyake T; Egawa-Takata T; Miyatake T; Matsuzaki S; Yokoyama T; Yoshino K; Fujita M; Enomoto T; Kimura T
Cancer Chemother Pharmacol; 2011 Apr; 67(4):829-35. PubMed ID: 20563809
[TBL] [Abstract][Full Text] [Related]
22. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
Roncolato F; Lindemann K; Willson ML; Martyn J; Mileshkin L
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012160. PubMed ID: 31588998
[TBL] [Abstract][Full Text] [Related]
23. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
24. Second-line lenvatinib in patients with recurrent endometrial cancer.
Vergote I; Powell MA; Teneriello MG; Miller DS; Garcia AA; Mikheeva ON; Bidzinski M; Cebotaru CL; Dutcus CE; Ren M; Kadowaki T; Funahashi Y; Penson RT
Gynecol Oncol; 2020 Mar; 156(3):575-582. PubMed ID: 31955859
[TBL] [Abstract][Full Text] [Related]
25. Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada.
Alimohamed N; Grewal S; Wirtz HS; Hepp Z; Sauvageau S; Boyne DJ; Brenner DR; Cheung WY; Jarada TN
Curr Oncol; 2022 Oct; 29(10):7587-7597. PubMed ID: 36290876
[TBL] [Abstract][Full Text] [Related]
26. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
[TBL] [Abstract][Full Text] [Related]
27. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
28. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.
McMeekin DS; Gordon A; Fowler J; Melemed A; Buller R; Burke T; Bloss J; Sabbatini P
Gynecol Oncol; 2003 Jul; 90(1):64-9. PubMed ID: 12821343
[TBL] [Abstract][Full Text] [Related]
30. Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Moss HA; Perhanidis JA; Havrilesky LJ; Secord AA
Gynecol Oncol; 2021 Oct; 163(1):50-56. PubMed ID: 34301411
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).
Moreira E; Paulino E; Ingles Garces ÁH; Fontes Dias MS; Saramago M; de Moraes Lino da Silva F; Thuler LCS; de Melo AC
Med Oncol; 2018 Jan; 35(3):20. PubMed ID: 29387971
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.
Sovak MA; Dupont J; Hensley ML; Ishill N; Gerst S; Abu-Rustum N; Anderson S; Barakat R; Konner J; Poyner E; Sabbatini P; Spriggs DR; Aghajanian C
Int J Gynecol Cancer; 2007; 17(1):197-203. PubMed ID: 17291253
[TBL] [Abstract][Full Text] [Related]
33. Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer.
Ninomiya T; Yamagami W; Susumu N; Makabe T; Sakai K; Wada M; Takigawa A; Chiyoda T; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
Anticancer Res; 2016 Apr; 36(4):1751-8. PubMed ID: 27069155
[TBL] [Abstract][Full Text] [Related]
34. Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.
Sclafani F; Morano F; Cunningham D; Baratelli C; Kalaitzaki E; Watkins D; Starling N; Chau I; Rao S
Oncologist; 2017 Apr; 22(4):402-408. PubMed ID: 28209745
[TBL] [Abstract][Full Text] [Related]
35. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm.
Goulden S; Shen Q; Coleman RL; Mathews C; Hunger M; Pahwa A; Schade R
J Health Econ Outcomes Res; 2023; 10(2):53-61. PubMed ID: 37701519
[No Abstract] [Full Text] [Related]
36. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.
Vale CL; Tierney J; Bull SJ; Symonds PR
Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD003915. PubMed ID: 22895938
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Sato H; Tsukahara K; Okamoto I; Katsube Y; Shimizu A; Kondo T; Hanyu K; Fushimi C; Okada T; Miura K
Acta Otolaryngol; 2019 Feb; 139(2):201-205. PubMed ID: 30794080
[TBL] [Abstract][Full Text] [Related]
38. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
39. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
[TBL] [Abstract][Full Text] [Related]
40. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]